The Prime Minister's Economic Advisory Council has suggested a complex combination of three pricing models to fix retail prices of 348 essential drugs to balance industry's concerns and public health. The proposal, however, has drawn the ire of drug makers who say it is a watered down version of the health ministry's proposals. The council has proposed that for medicines facing "insufficient competition" or a monopoly-like situation, the retail price should...

 Madhya Pradesh cancelled licences of seven 'gutkha' companies and banned its manufacture and sale in the state from April 1. MP is the first state in the country to ban tobacco, magnesium carbonate and nicotine-based 'gutkha' following provisions of the Food Safety and Standards (Prohibition and Restriction on Sales) Regulation 2011.  Health minister and government spokesman Narottam Mishra said gutkha manufacturing licences in the state will not be renewed. "Gutkha makers...

-The Hindu Moving towards major reforms, the Centre is in the process of rolling out a universal health coverage package in at least one district in each State on an experimental basis. This would include a clearly defined basket of services to those who come to any public health facility for treatment or free supply of generic drugs, doing away with user charges and upgrading public health infrastructure right from the primary...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.  The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make...